Cargando…
Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
In 20 patients with cisplatin-associated anaemia (haemoglobin less than 90 gl-1), recombinant human erythropoietin was administered subcutaneously three times a week on an outpatient basis. The initial dose was 50 Units Kg-1 of body weight. If response was not achieved within 3 weeks, dose was incre...
Autores principales: | Cascinu, S., Fedeli, A., Fedeli, S. L., Catalano, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968216/ https://www.ncbi.nlm.nih.gov/pubmed/8427776 |
Ejemplares similares
-
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
por: Cascinu, S., et al.
Publicado: (1994) -
Erythropoietin, uncertainty principle and cancer related anaemia
por: Clark, Otavio, et al.
Publicado: (2002) -
Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
por: Barosi, G., et al.
Publicado: (1998) -
Anaemia at discharge from the intensive care unit is associated with an inappropriate erythropoietin response
por: Bateman, A, et al.
Publicado: (2005) -
Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)